Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Debt (2016 - 2025)

Cytosorbents' Total Debt history spans 9 years, with the latest figure at $16.7 million for Q4 2025.

  • Quarterly results put Total Debt at $16.7 million for Q4 2025, up 19.08% from a year ago — trailing twelve months through Dec 2025 was $16.7 million (up 19.08% YoY), and the annual figure for FY2025 was $16.7 million, up 19.08%.
  • Total Debt for Q4 2025 was $16.7 million at Cytosorbents, up from $14.6 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $16.7 million in Q4 2025 to a low of $4.4 million in Q1 2024.
  • The 4-year median for Total Debt is $13.7 million (2024), against an average of $10.5 million.
  • The sharpest move saw Total Debt rose 0.86% in 2023, then skyrocketed 220.35% in 2025.
  • Year by year, Total Debt stood at $5.0 million in 2022, then rose by 0.86% to $5.0 million in 2023, then surged by 177.54% to $14.0 million in 2024, then increased by 19.08% to $16.7 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $16.7 million, $14.6 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.